207 related articles for article (PubMed ID: 11257409)
1. Technologies for the design, discovery, formulation and administration of vaccines.
Ellis RW
Vaccine; 2001 Mar; 19(17-19):2681-7. PubMed ID: 11257409
[TBL] [Abstract][Full Text] [Related]
2. [The future of vaccines: recombinant DNA vaccines].
van Dam RH; Keus RJ
Tijdschr Diergeneeskd; 1990 May; 115(9):413-9. PubMed ID: 2188394
[TBL] [Abstract][Full Text] [Related]
3. [The outlook for developing recombinant vaccines based on mycobacteria].
Lazarenko VN; Makhlaĭ AA; Khomenko AG
Vestn Ross Akad Med Nauk; 1993; (2):37-9. PubMed ID: 7688618
[TBL] [Abstract][Full Text] [Related]
4. Applications and challenges of multivalent recombinant vaccines.
Naim HY
Hum Vaccin Immunother; 2013 Mar; 9(3):457-61. PubMed ID: 23249651
[TBL] [Abstract][Full Text] [Related]
5. Vaccination today and tomorrow.
Brown F
Biosci Rep; 1995 Dec; 15(6):493-502. PubMed ID: 9156579
[TBL] [Abstract][Full Text] [Related]
6. Bacterial infectious disease control by vaccine development.
Curtiss R
J Clin Invest; 2002 Oct; 110(8):1061-6. PubMed ID: 12393839
[No Abstract] [Full Text] [Related]
7. [The prospects for the development of viral vaccines].
Bektimirov TA; Gorbunov MA
Voen Med Zh; 1995 Jul; (7):45-8. PubMed ID: 7571512
[No Abstract] [Full Text] [Related]
8. Novel vaccination approaches against equine alphavirus encephalitides.
Carossino M; Thiry E; de la Grandière A; Barrandeguy ME
Vaccine; 2014 Jan; 32(3):311-9. PubMed ID: 24295803
[TBL] [Abstract][Full Text] [Related]
9. From vaccine research to manufacture: a guide for the researcher.
Allison N; Tranter HS
Methods Mol Med; 2003; 87():391-408. PubMed ID: 12958469
[No Abstract] [Full Text] [Related]
10. [The conditions for modern vaccine development].
Murphy FA
Zh Mikrobiol Epidemiol Immunobiol; 1990 Nov; (11):83-90. PubMed ID: 2097852
[No Abstract] [Full Text] [Related]
11. The Immunotherapeutics and Vaccine Summit - CHI's fifth annual meeting - novel vaccines: adjuvants and delivery systems: part 2.
Jones SD
IDrugs; 2010 Oct; 13(10):692-4. PubMed ID: 20878589
[TBL] [Abstract][Full Text] [Related]
12. Foot-and-mouth disease vaccines: progress and problems.
Cao Y; Lu Z; Liu Z
Expert Rev Vaccines; 2016 Jun; 15(6):783-9. PubMed ID: 26760264
[TBL] [Abstract][Full Text] [Related]
13. Herpes simplex viruses: is a vaccine tenable?
Whitley RJ; Roizman B
J Clin Invest; 2002 Jul; 110(2):145-51. PubMed ID: 12122103
[No Abstract] [Full Text] [Related]
14. [Adjuvants--essential components of new generation vaccines].
Dzierzbicka K; Kołodziejczyk AM
Postepy Biochem; 2006; 52(2):204-11. PubMed ID: 17078510
[TBL] [Abstract][Full Text] [Related]
15. Highly attenuated poxvirus vectors: NYVAC, ALVAC and TROVAC.
Paoletti E; Taylor J; Meignier B; Meric C; Tartaglia J
Dev Biol Stand; 1995; 84():159-63. PubMed ID: 7796949
[TBL] [Abstract][Full Text] [Related]
16. Current status of DNA vaccines and their route of administration.
Alpar HO; Bramwell VW
Crit Rev Ther Drug Carrier Syst; 2002; 19(4-5):307-83. PubMed ID: 12661697
[TBL] [Abstract][Full Text] [Related]
17. Lactococcus lactis-based vaccines: current status and future perspectives.
Bahey-El-Din M; Gahan CG
Hum Vaccin; 2011 Jan; 7(1):106-9. PubMed ID: 21263226
[TBL] [Abstract][Full Text] [Related]
18. [Modern methods for the development of antiviral vaccines].
Raadsen MP; van Leeuwen LPM; van Gorp ECM; de Swart RL; Haagmans BL
Ned Tijdschr Geneeskd; 2020 Sep; 164():. PubMed ID: 33030319
[TBL] [Abstract][Full Text] [Related]
19. Live attenuated and inactivated viral vaccine formulation and nasal delivery: potential and challenges.
Tlaxca JL; Ellis S; Remmele RL
Adv Drug Deliv Rev; 2015 Oct; 93():56-78. PubMed ID: 25312673
[TBL] [Abstract][Full Text] [Related]
20. Adjuvants enhancing an integral immune response to antigens. 15-17 September, 2004, Modern Vaccine/Adjuvant Formulation: impact on future development (MVAF 2004), Prague.
van der Laan JW
Expert Rev Vaccines; 2005 Feb; 4(1):15-8. PubMed ID: 15757468
[No Abstract] [Full Text] [Related]
[Next] [New Search]
